Can Abbott’s AI Innovation and Dividend Track Record Propel Its Shares?
Published on 01/16/2026 at 09:42 | Redaktion boerse-global.de
As Abbott Laboratories prepares to release its quarterly earnings, investor focus is split between a promising new product announcement and the company’s enduring commitment to shareholder returns. The medical device giant recently showcased its latest innovation at CES 2026, while simultaneously extending a notable dividend record.
The spotlight at the tech conference fell on ‘Libre Assist,’ a new AI-powered feature for Abbott’s FreeStyle Libre continuous glucose monitoring ecosystem. Unlike traditional retrospective data, this tool aims to predict an individual’s glucose response to specific foods, offering recommendations before a meal. This proactive approach addresses a significant practical challenge for diabetes management and could strengthen Abbott’s competitive position in Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
